【原文】M13A:口服固体速释制剂的生物等效性(初稿)

本指导原则旨在为研发和上市后阶段设计递送药物至体循环的口服固体速释(IR)制剂(如片剂、胶囊剂、用于口服混悬液的颗粒剂/粉剂)开展生物等效性(BE)研究提供建议。

文书类别:药品/文件依据/法规文件 文书页数:31页 更新时间:2023-02-15

应用地区:全国 应用岗位:口服固体速释制剂 法规依据:/

¥ 0.00
预览显示加载中
占位
INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE BIOEQUIVALENCE FOR IMMEDIATE - RELEASE SOLID ORAL DOSAGE FORMS M13 A Draft version Endorsed on 20 December 2022 Currently under public consultation At Step 2 of the ICH Process, a consensus draft text or guideline, agreed by the appropriate ICH Expert Working Group, is transmitted by the ICH Assembly to the regulatory authorities of the ICH regions for internal and external consultation, according to national or regional procedures.

展开

在线咨询
回到顶部